Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Newer Form of Heparin Better at Preventing Clots After Stroke

Enoxaparin cut the risk by additional 43 percent, study found

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Alzheimer's Disease
Aneurysms
Angina Pectoris
Angiogram
More...

Related Healthscout Videos
 border=
Howard: The Helping Hand for Stroke Survivors
Fixing Torn Hearts
Medicine's Next Big Thing? Growing Hearts
How can a supportive family help?
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Animation: What is Hypertension?
Coronary Bypass Surgery
More...

Related Drug Information
 border=
Accupril
Actonel
Altace
Avapro
More...

Related News Articles
 border=
Researchers Identify New Genetic Links to Psoriasis
While Hospice Care Is Growing, Not All Have Access
Few Countries on Track to Curb Maternal, Child Mortality Rates
When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side
More...

THURSDAY, April 19 (HealthDay News) -- A newly engineered form of the blood-thinning drug heparin has proven more effective at preventing life-threatening clots in people who suffer strokes than the older version of the drug, a new study finds.

The incidence of clots in the lungs and legs of stroke patients who got the engineered form, called enoxaparin, was 43 percent lower than in those who got ordinary heparin, researchers said.

Text Continues Below



"This is the first big trial in which the two treatments have gone head to head," said lead researcher Dr. David G. Sherman, a professor of medicine and neurology at the University of Texas Health Science Center, in San Antonio. "Enoxaparin pretty convincingly appears to work better."

"Now that the results have been published, the question is, what will the bodies that write guidelines for management of stroke do?" Sherman added. "Because the results are so consistent, my guess is that the guidelines will say that stroke patients should be anticoagulated and that, because enoxaparin appears to be most efficient, it will become the standard."

The trial was funded by Sanofi Aventis, the maker of enoxaparin (Lovenox).

The finding, reported in the April 21 issue of The Lancet, is potentially applicable to more than 700,000 people who suffer strokes in the United States each year, Sherman said. These patients are at high risk of clotting because of their forced inactivity. In fact, the 1,762 stroke patients in the study received anticoagulant treatment only if they were unable to walk.

Half of the patients were given one injection of enoxaparin a day, the other half received two daily injections of heparin. They were then studied for the presence of blood clots in the legs and lungs.

The study included only patients who suffered ischemic stroke, the most common kind. In this type of attack a blood clot blocks a brain artery. However, Sherman said there are indications that the results also apply to people who have hemorrhagic strokes, in which a blood vessel bursts.

Page:  1 | 2 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 4/20/2007

Related Links
 border=
From Healthscout's partner site on cholesterol, CholesterolNetwork.com
VIDEO: Open Arteries with a Cancer Drug
ONLINE TEST: Take our Home Body Fat Test!
QUIZ: Recommended Daily Calories and Fat





New Features

New ADHD Site!

SOURCES: David G. Sherman, M.D., professor, medicine and neurology, University of Texas Health Science Center at San Antonio; Richard M. Weinberg, M.D., chief quality officer, Stamford Health System, Stamford, Conn; April 21, 2007, The Lancet


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map